MedPlus Health Services Subsidiary Faces Drug License Suspensions Across Multiple Stores

MedPlus Health Services Limited has informed stock exchanges about drug license suspensions affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, its subsidiary, received six suspension orders from drug control authorities in Karnataka and Telangana.

Regulatory Actions and Store Locations

The suspension orders were issued by drug control administration authorities across two states, affecting multiple store locations with varying suspension periods.

Authority	Store Locations	Suspension Period	Order Date	Revenue Impact
Assistant Director, Drugs Control Administration, Bangalore Circle-2	Ritecure South City Hospital Premises, New Srinagar	2 days each	January 10, 2026	₹0.23 lakhs
Assistant Director, Drugs Control Administration, Bangalore Circle-2	Hanumanth Nagar New, Srinagar Bus Stand	2 days each	January 10, 2026	₹1.45 lakhs, ₹1.08 lakhs
Assistant Director, Drugs Control Administration, Bangalore Circle-2	Karnataka (location specified)	2 days	January 10, 2026	₹1.69 lakhs
Assistant Director, Drugs Control Administration, Nalgonda	Thirumalagiri, Telangana	4 days	January 12, 2026	₹1.08 lakhs
Assistant Director, Drugs Control Administration, Patancheruvu	Eidgah Road Krishnareddypet, Telangana	1 day	Order received	₹0.45 lakhs

Legal Framework and Compliance

The suspension orders were issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The company has disclosed this information in compliance with Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The disclosure follows SEBI circulars SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, which mandate detailed reporting of regulatory actions.

Financial Impact Assessment

The company has quantified the potential revenue loss from these suspensions across all affected stores:

Impact Category	Amount
Total Potential Revenue Loss	₹6.98 lakhs
Highest Individual Store Impact	₹1.69 lakhs
Lowest Individual Store Impact	₹0.23 lakhs

Regulatory Disclosure

MedPlus Health Services has made this disclosure through proper channels to both BSE Limited and National Stock Exchange of India Limited. The information will be available on the company's website at www.medplusindia.com and on the respective stock exchange websites. Company Secretary and Compliance Officer Manoj Kumar Srivastava signed the regulatory filing on January 13, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.34%	+1.30%	+4.82%	-3.55%	+3.43%	-24.78%

MedPlus Health Services has informed stock exchanges about a regulatory action affecting one of its subsidiary operations in Karnataka. The company disclosed that Optival Health Solutions Private Limited, a subsidiary of MedPlus Health Services, received a suspension order for a drug license at one of its retail locations.

Regulatory Action Details

The suspension order was issued by the Assistant Director of Drugs Control Administration, Gadag Circle, Karnataka, and was received by the company on January 2, 2026. The action specifically targets the store situated at KC Rani Road, Gadag, Karnataka, with the drug license suspended for a duration of one day.

Parameter:	Details
Issuing Authority:	Assistant Director, Drugs Control Administration, Gadag Circle, Karnataka
Nature of Action:	Drug License Suspension
Duration:	One day
Store Location:	KC Rani Road, Gadag, Karnataka
Order Received:	January 2, 2026

Legal Framework and Violation

The suspension order was issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The company has disclosed this information in compliance with SEBI regulations, specifically under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The disclosure follows SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, which mandates companies to report such regulatory actions.

Financial Impact

The company has quantified the potential financial impact of this regulatory action. The estimated revenue loss from the one-day suspension amounts to approximately ₹0.23 lacs for the affected store location.

Impact Metric:	Amount
Potential Revenue Loss:	₹0.23 lacs
Duration of Impact:	One day

Compliance and Disclosure

MedPlus Health Services has ensured proper disclosure of this regulatory development through multiple channels. The information has been made available on the company's official website at www.medplusindia.com , as well as on the websites of both stock exchanges - BSE Limited and National Stock Exchange of India Limited.

The disclosure was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, demonstrating the company's commitment to maintaining transparency with stakeholders regarding regulatory matters affecting its subsidiary operations.